161 related articles for article (PubMed ID: 32477975)
1. Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study.
Sharma RK; Verma GK; Tegta GR; Sood S; Rattan R; Gupta M
Indian Dermatol Online J; 2020; 11(2):177-181. PubMed ID: 32477975
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of anti tubercular therapy induced cutaneous adverse drug reactions and its management through rechallenge: A prospective study at a Tertiary Care Centre.
Modi B; Modha J
Indian J Tuberc; 2022 Oct; 69(4):470-475. PubMed ID: 36460378
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous drug reaction secondary to antitubercular regimen: A case report from Nepal.
Bhattarai HB; Yadav J; Sapkota S; Adhikari A; Bhattarai M; Singh I; Shrestha S; Kc J; Karki P; Basnet B
SAGE Open Med Case Rep; 2023; 11():2050313X231210390. PubMed ID: 37954539
[TBL] [Abstract][Full Text] [Related]
5. Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy.
Sadiq S; Khajuria V; Tandon VR; Mahajan A; Singh JB
J Clin Diagn Res; 2015 Oct; 9(10):FC01-4. PubMed ID: 26557538
[TBL] [Abstract][Full Text] [Related]
6. Drug Reaction With Eosinophilia and Systemic Symptom (DRESS) Following Rifampicin Treatment: A Case Report.
Shrestha R; Jha SK; Bartaula J
Cureus; 2021 Nov; 13(11):e19223. PubMed ID: 34873548
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
8. Lichenoid drug reaction due to anti-tubercular therapy presenting as erythroderma.
Katare A; Arora P; Sardana K; Malhotra P
Dermatol Ther; 2020 Jan; 33(1):e13169. PubMed ID: 31747108
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis.
Potter J; Agrawal R; Barraclough C; Rahman F; Westcott M; Pavesio CE; White V
Ocul Immunol Inflamm; 2016 Oct; 24(5):508-14. PubMed ID: 26222893
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
Lehloenya RJ; Todd G; Badri M; Dheda K
Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173
[TBL] [Abstract][Full Text] [Related]
11. Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting.
Basu S; Nayak S; Padhi TR; Das T
Eye (Lond); 2013 May; 27(5):657-62. PubMed ID: 23449506
[TBL] [Abstract][Full Text] [Related]
12. Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study.
Nene AM; Patil S; Kathare AP; Nagad P; Nene A; Kapadia F
Spine (Phila Pa 1976); 2019 Jan; 44(1):E1-E6. PubMed ID: 30045346
[TBL] [Abstract][Full Text] [Related]
13. Drug sensitivity patterns in Xpert-positive spinal tuberculosis: an observational study of 252 patients.
Upadhyay M; Patel J; Kundnani V; Ruparel S; Patel A
Eur Spine J; 2020 Jul; 29(7):1476-1482. PubMed ID: 32055960
[TBL] [Abstract][Full Text] [Related]
14. Antitubercular drug-induced lichen planus: A case study with a mini literature review.
Shanmukhappa SC; John W; Kevalramani V; Lokeshwaran S; Furtado S; Nosenoor M
J Family Med Prim Care; 2024 Feb; 13(2):438-443. PubMed ID: 38605770
[TBL] [Abstract][Full Text] [Related]
15. Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection.
Costiniuk CT; Gosnell BI; Manzini TC; Du Plessis CN; Moosa MY
J Glob Infect Dis; 2015; 7(4):151-6. PubMed ID: 26752869
[TBL] [Abstract][Full Text] [Related]
16. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Dhingra VK; Rajpal S; Mittal A; Hanif M
Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
[TBL] [Abstract][Full Text] [Related]
17. Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting.
Alvarez-Uria G; Midde M; Naik PK
PeerJ; 2016; 4():e2053. PubMed ID: 27231666
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Trial of Jawarish Amla as Adjuvant to Anti-Tubercular Treatment Drugs for Control of Adverse Reactions in DOTS Regime in Pulmonary TB.
Sherwani AM; Zulkifle M; Rehmatulla
J IMA; 2012; 44(1):. PubMed ID: 23864996
[TBL] [Abstract][Full Text] [Related]
19. Newer trends in tubercular uveitis: a case series with systemic correlation.
Annamalai R; Mohanakumar M; Raghu K; Muthayya M
Int J Ophthalmol; 2020; 13(11):1739-1744. PubMed ID: 33215004
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment.
Bartoletti M; Martelli G; Tedeschi S; Morelli M; Bertuzzo V; Tadolini M; Pianta P; Cristini F; Giannella M; Lewis RE; Pinna AD; Viale P
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28054732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
